Note 15 - Segments (Tables)

3 Months Ended

Mar. 31, 2021

Three Months Ended March 31, 2021	Diagnostics			Therapeutics			Corporate			Total
License revenue	$	22,486		$	—		$	—		$	22,486
Grant and other revenue		101,251			—			—			101,251
Total revenue		123,737			—			—			123,737
Cost of revenue		—			—			—			—
Research and development expenses		1,094,390			128,364			—			1,222,754
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			2,006			2,210,991			2,212,997
Depreciation and amortization (2)		6,040			—			11,708			17,748
Loss from operations (3)		(976,693	)		(130,370	)		(2,222,699	)		(3,329,762	)
Other income (4)		—			—			362,870			362,870
Net loss		(976,693	)		(130,370	)		(1,859,829	)		(2,966,892	)
Total assets, net of depreciation and amortization:
United States	$	160,669		$	—		$	9,723,212		$	9,883,881
International		193,194			—			—			193,194
Capital expenditures		—			—			—			—

Three Months Ended March 31, 2020	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	15,221		$	—		$	—		$	15,221
Grant and other revenue		58,916			82,135			—			141,051
Total revenue		74,137			82,135			—			156,272
Cost of revenue		609			—			—			609
Research and development expenses		957,626			41,643			—			999,269
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			(1,522	)		1,812,433			1,810,911
Depreciation and amortization (2)		—			—			16,843			16,843
(Loss) income from operations (3)		(884,098	)		42,014			(1,829,276	)		(2,671,360	)
Other expense (4)		—			—			(2,248	)		(2,248	)
Net loss		(884,098	)		42,014			(1,831,524	)		(2,673,608	)
Total assets, net of depreciation and amortization:
United States	$	36,671		$	2,494		$	4,438,066		$	4,477,231
International		—			—			—			—
Capital expenditures		—			—			6,459			6,459